Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 175

Similar articles for PubMed (Select 22995877)

1.

Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial.

Savonitto S, Cavallini C, Petronio AS, Murena E, Antonicelli R, Sacco A, Steffenino G, Bonechi F, Mossuti E, Manari A, Tolaro S, Toso A, Daniotti A, Piscione F, Morici N, Cesana BM, Jori MC, De Servi S; Italian Elderly ACS Trial Investigators.

JACC Cardiovasc Interv. 2012 Sep;5(9):906-16. doi: 10.1016/j.jcin.2012.06.008.

2.

Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.

Pride YB, Mohanavelu S, Zorkun C, Kunadian V, Giugliano RP, Newby LK, Braunwald E, Califf RM, Harrington RA, Gibson CM; EARLY ACS Investigators.

JACC Cardiovasc Interv. 2012 Sep;5(9):927-35. doi: 10.1016/j.jcin.2012.05.007.

3.

Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.

Vavalle JP, Clare R, Chiswell K, Rao SV, Petersen JL, Kleiman NS, Mahaffey KW, Wang TY.

JACC Cardiovasc Interv. 2013 Jul;6(7):709-17. doi: 10.1016/j.jcin.2013.03.010.

5.
6.

Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction.

Roe MT, Li S, Thomas L, Wang TY, Alexander KP, Ohman EM, Peterson ED.

Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):323-32. doi: 10.1161/CIRCOUTCOMES.113.000120. Epub 2013 May 7.

7.

Effect of an invasive strategy on outcome in patients ≥75 years of age with non-ST-elevation acute coronary syndrome.

Galasso G, De Servi S, Savonitto S, Strisciuglio T, Piccolo R, Morici N, Murena E, Cavallini C, Petronio AS, Piscione F.

Am J Cardiol. 2015 Mar 1;115(5):576-80. doi: 10.1016/j.amjcard.2014.12.005. Epub 2014 Dec 18.

PMID:
25595527
8.

Disease distribution and outcome in troponin-positive patients with or without revascularization in a chest pain unit: results of the German CPU-Registry.

Illmann A, Riemer T, Erbel R, Giannitsis E, Hamm C, Haude M, Heusch G, Maier LS, Münzel T, Schmitt C, Schumacher B, Senges J, Voigtländer T, Mudra H.

Clin Res Cardiol. 2014 Jan;103(1):29-40.

PMID:
24077679
9.

Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome).

Puymirat E, Taldir G, Aissaoui N, Lemesle G, Lorgis L, Cuisset T, Bourlard P, Maillier B, Ducrocq G, Ferrieres J, Simon T, Danchin N.

JACC Cardiovasc Interv. 2012 Sep;5(9):893-902. doi: 10.1016/j.jcin.2012.05.008.

10.

Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Nikolsky E, McLaurin BT, Cox DA, Manoukian SV, Xu K, Mehran R, Stone GW.

JACC Cardiovasc Interv. 2012 Sep;5(9):919-26. doi: 10.1016/j.jcin.2012.06.009.

11.

Stress CMR reduces revascularization, hospital readmission, and recurrent cardiac testing in intermediate-risk patients with acute chest pain.

Miller CD, Case LD, Little WC, Mahler SA, Burke GL, Harper EN, Lefebvre C, Hiestand B, Hoekstra JW, Hamilton CA, Hundley WG.

JACC Cardiovasc Imaging. 2013 Jul;6(7):785-94. doi: 10.1016/j.jcmg.2012.11.022. Epub 2013 May 8.

12.

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, Moliterno DJ, Van de Werf F, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW.

J Am Coll Cardiol. 2014 Mar 25;63(11):1048-57. doi: 10.1016/j.jacc.2013.10.048. Epub 2013 Nov 21.

13.

Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.

Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.

JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011.

14.

Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial.

Badings EA, The SH, Dambrink JH, van Wijngaarden J, Tjeerdsma G, Rasoul S, Timmer JR, van der Wielen ML, Lok DJ, van 't Hof AW.

EuroIntervention. 2013 May 20;9(1):54-61. doi: 10.4244/EIJV9I1A9.

15.
16.

Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation.

Mehta SR, Jolly SS, Cairns J, Niemela K, Rao SV, Cheema AN, Steg PG, Cantor WJ, Džavík V, Budaj A, Rokoss M, Valentin V, Gao P, Yusuf S; RIVAL Investigators.

J Am Coll Cardiol. 2012 Dec 18;60(24):2490-9. doi: 10.1016/j.jacc.2012.07.050. Epub 2012 Oct 24.

17.

Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, Argenziano M, Williams MR, Colombo A, Aylward PE, Stone GW.

JACC Cardiovasc Interv. 2010 Oct;3(10):1059-67. doi: 10.1016/j.jcin.2010.06.017.

18.

Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.

Toleva O, Westerhout CM, Senaratne MP, Bode C, Lindroos M, Sulimov VA, Montalescot G, Newby LK, Giugliano RP, Van de Werf F, Armstrong PW.

Catheter Cardiovasc Interv. 2014 Nov 15;84(6):934-42. doi: 10.1002/ccd.25590. Epub 2014 Jul 9.

PMID:
24976083
19.

Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US sites versus non-US sites? Analysis from the ACUITY trial.

Tobbia P, Brodie BR, Stuckey T, McLaurin BT, Cox DA, Fahy M, Xu K, Mehran R, Stone GW.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E365-74. doi: 10.1002/ccd.24587. Epub 2013 Mar 9.

PMID:
22887494
20.

Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.

Bagai A, White JA, Lokhnygina Y, Giugliano RP, Van de Werf F, Montalescot G, Armstrong PW, Tricoci P, Gibson CM, Califf RM, Harrington RA, Newby LK.

Am Heart J. 2013 Sep;166(3):466-73. doi: 10.1016/j.ahj.2013.05.019. Epub 2013 Jul 25.

PMID:
24016495
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk